Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-<i>Helicobacter pylori</i> Treatment in Real World Clinical Practice.

Infect Drug Resist · 2021 · PMC8007608 · PMID 33790594

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

30 Boltin et al reported the esomeprazole did not show a significant trend over omeprazole among subjects receiving quadruple therapy. 31 These reports were similar with to the current findings.

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.